Chancery Stays Suit Over Drug Trial Disclosure Failures
By Jeff Montgomery ( June 6, 2022, 3:44 PM EDT) -- Stockholders who sued a biotech company for alleged failures to disclose bad news about drug trials for the company's lone product in 2017 have had their Delaware Chancery Court case put on hold while a more fully developed federal securities action targeting the same clinical trial failure moves forward....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.